Information  X 
Enter a valid email address

Positive results in viral pneumonia study for Synairgen

By BFN News | 08:53 AM | Friday 25 November, 2011


Synairgen, the respiratory drug discovery and development company has announced positive data from its pre-clinical study evaluating the effectiveness of aerosolised interferon beta ('IFN-beta') against viral pneumonia. Richard Marsden, CEO of Synairgen, commented, "We are very encouraged by data which supports the further development of IFN-beta as a novel therapeutic approach to the threats posed by respiratory viruses such as influenza, new emerging viruses and aerosolised bioterrorism threats. This development complements our current program targeting viral infections in asthma sufferers, which is drawing near to the end of its Phase II proof of concept study." At 8:53am: (LON:SNG) Synairgen share price was +1p at 33p Story provided by StockMarketWire.com

a d v e r t i s e m e n t